RESUMO
BACKGROUND: Typhoid fever is common in developing countries. The licensed typhoid vaccines confer only about 70 percent immunity, do not protect young children, and are not used for routine vaccination. A newly devised conjugate of the capsular polysaccharide of Salmonella typhi, Vi, bound to nontoxic recombinant Pseudomonas aeruginosa exotoxin A (rEPA), has enhanced immunogenicity in adults and in children 5 to 14 years old and has elicited a booster response in children 2 to 4 years old. METHODS: In a double-blind, randomized trial, we evaluated the safety, immunogenicity, and efficacy of the Vi-rEPA vaccine in children two to five years old in 16 communes in Dong Thap Province, Vietnam. Each of the 11,091 children received two injections six weeks apart of either Vi-rEPA or a saline placebo. Cases of typhoid, diagnosed by the isolation of S. typhi from blood cultures after 3 or more days of fever (a temperature of 37.5 degrees C or higher), were identified by active surveillance over a period of 27 months. We estimated efficacy by comparing the attack rate of typhoid in the vaccine group with that in the placebo group. RESULTS: S. typhi was isolated from 4 of the 5525 children who were fully vaccinated with Vi-rEPA and from 47 of the 5566 children who received both injections of placebo (efficacy, 91.5 percent; 95 percent confidence interval, 77.1 to 96.6; P<0.001). Among the 771 children who received only one injection, there was 1 case of typhoid in the vaccine group and 8 cases in the placebo group. Cases were distributed evenly among all age groups and throughout the study period. No serious adverse reactions were observed. In all 36 children studied four weeks after the second injection of the vaccine, levels of serum IgG Vi antibodies had increased by a factor of 10 or more. CONCLUSIONS: The Vi-rEPA conjugate typhoid vaccine is safe and immunogenic and has more than 90 percent efficacy in children two to five years old. The antibody responses and the efficacy suggest that this vaccine should be at least as protective in persons who are more than five years old.
Assuntos
ADP Ribose Transferases , Toxinas Bacterianas , Polissacarídeos Bacterianos , Febre Tifoide/prevenção & controle , Vacinas Tíficas-Paratíficas , Fatores de Virulência , Anticorpos Antibacterianos/sangue , Pré-Escolar , Método Duplo-Cego , Exotoxinas , Feminino , Humanos , Imunoglobulina G/sangue , Masculino , Polissacarídeos Bacterianos/efeitos adversos , Polissacarídeos Bacterianos/imunologia , Salmonella typhi/imunologia , Resultado do Tratamento , Febre Tifoide/imunologia , Vacinas Tíficas-Paratíficas/efeitos adversos , Vacinas Tíficas-Paratíficas/imunologia , Vacinas Conjugadas/efeitos adversos , Vacinas Conjugadas/imunologia , Exotoxina A de Pseudomonas aeruginosaRESUMO
Data suggest that the O-specific polysaccharide (O-SP) domain of the lipopolysaccharide (LPS) of Shigella species is both an essential virulence factor and a protective antigen and that a critical level of serum immunoglobulin G (IgG) to this antigen will confer immunity to shigellosis. Because covalent attachment of polysaccharides to proteins increases their immunogenicity, especially in infants and in young children, the O-SP of Shigella species were bound to medically useful proteins, and the safety and immunogenicity of the resultant conjugates were confirmed in adults and 4- to 7-year-old children. Succinylation of the carrier protein improved the immunogenicity of Shigella conjugates in mice and increased their yield. Based on these results, a clinical trial of O-SP conjugates of Shigella sonnei and Shigella flexneri 2a bound to succinylated mutant Pseudomonas aeruginosa exotoxin A (rEPAsucc) or native or succinylated Corynebacterium diphtheriae toxin mutant (CRM9 or CRM9succ) was conducted in healthy adults. The conjugates were safe and immunogenic. S. sonnei-CRM9, S. sonnei-CRM9succ, and S. sonnei-rEPAsucc elicited significant rises of geometric mean (GM) IgG anti-LPS within 1 week of injection (P < 0.001). At 26 weeks, the GM anti-LPS levels elicited by these three conjugates were similar and higher than their prevaccination levels (P < 0.0001). GM IgG anti-LPS levels elicited by S. flexneri 2a-rEPAsucc were significantly higher than those elicited by S. flexneri 2a-rCRM9succ at all intervals after injection. At 26 weeks, the levels of IgG anti-LPS in vaccinees were higher than their prevaccination levels (P < 0.0001). The serum antibody responses were specific, as there was no significant rise of anti-LPS to the heterologous O-SP in any vaccinee. Both conjugates elicited statistically significant rises of serum antibodies to the injected carrier protein. At 6 months, these five Shigella conjugates elicited higher fold rises than similar conjugates (D. N. Taylor et al., Infect. Immun. 61:3678-3687, 1993). Based on these data, we chose S. sonnei-CRM9 and S. flexneri 2a-rEPAsucc for evaluation in children.
Assuntos
Disenteria Bacilar/prevenção & controle , Antígenos O/uso terapêutico , Vacinas contra Shigella/uso terapêutico , Vacinas Conjugadas/uso terapêutico , Adolescente , Adulto , Anticorpos Antibacterianos/sangue , Proteínas de Bactérias/imunologia , Proteínas de Bactérias/uso terapêutico , Feminino , Humanos , Imunoglobulina A/sangue , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Israel , MasculinoRESUMO
Unlike the native protein, a nontoxic peptide (repeating unit of the native toxin designated rARU) from Clostridium difficile toxin A (CDTA) afforded an antigen that could be bound covalently to the surface polysaccharides of pneumococcus type 14, Shigella flexneri type 2a, and Escherichia coli K1. The yields of these polysaccharide-protein conjugates were significantly increased by prior treatment of rARU with succinic anhydride. Conjugates, prepared with rARU or succinylated (rARUsucc), were administered to mice by a clinically relevant dosage and immunization scheme. All conjugates elicited high levels of serum immunoglobulin G both to the polysaccharides and to CDTA. Conjugate-induced anti-CDTA had neutralizing activity in vitro and protected mice challenged with CDTA, similar to the rARU alone. Conjugates prepared with succinylated rARU, therefore, have potential for serving both as effective carrier proteins for polysaccharides and for preventing enteric disease caused by C. difficile.
Assuntos
Toxinas Bacterianas/imunologia , Proteínas de Transporte/imunologia , Clostridioides difficile/imunologia , Enterotoxinas/imunologia , Escherichia coli/imunologia , Polissacarídeos Bacterianos/imunologia , Shigella flexneri/imunologia , Streptococcus pneumoniae/imunologia , Vacinas Conjugadas/imunologia , Animais , Toxinas Bacterianas/genética , Sequência de Carboidratos , Enterotoxinas/genética , Ensaio de Imunoadsorção Enzimática , Feminino , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Camundongos , Dados de Sequência Molecular , Polissacarídeos Bacterianos/metabolismo , Proteínas Recombinantes/imunologia , Anidridos Succínicos/metabolismo , Vacinas Conjugadas/químicaRESUMO
All acellular pertussis vaccines contain pertussis toxoid and induce protection against pertussis. This study investigated the relation between the postvaccination levels of pertussis toxin (PT) serum IgG and protection against pertussis. PT IgG was determined in sera obtained 21-77 days after the third vaccination from 813 children who received 3 doses of pertussis toxoid. The children were followed for 21-33 months after vaccination for the occurrence of pertussis. Of the children, 126 were exposed to pertussis in their households. The median PT IgG concentration was 79 U/mL in those who developed severe pertussis (>/=21 day of paroxysmal cough), 156 U/mL with mild pertussis (<21 days of paroxysmal cough), and 246 U/mL in those who did not develop pertussis (79 vs. 246, P<.0001). Corresponding values in the 687 children with no household exposure were 99, 124, and 155 U/mL, respectively (99 vs. 155, P<.0001). Thus, there is a highly significant correlation between the level of vaccine-induced serum PT IgG and protection against pertussis.
Assuntos
Anticorpos Antibacterianos/sangue , Imunoglobulina G/sangue , Toxina Pertussis , Vacina contra Coqueluche/imunologia , Fatores de Virulência de Bordetella/imunologia , Coqueluche/prevenção & controle , Método Duplo-Cego , Humanos , Lactente , Fatores de Tempo , VacinaçãoRESUMO
Salmonella enterica serovar Paratyphi A O-specific polysaccharide (O-SP) was activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) and bound to tetanus toxoid (TT) with adipic acid dihydrazide as a linker (SPA-TT(1)) or directly (SPA-TT(2)). In mice, these two conjugates elicited high levels of immunoglobulin G (IgG) anti-lipopolysaccharide (LPS) in serum with bactericidal activity (E. Konadu, J. Shiloach, D. A. Bryla, J. B. Robbins, and S. C. Szu, Infect. Immun. 64:2709-2715, 1996). The safety and immunogenicity of the two conjugates were then evaluated sequentially in Vietnamese adults, teenagers, and 2- to 4-year-old children. None of the vaccinees experienced significant side effects, and all had preexisting LPS antibodies. At 4 weeks after injection, there were significant increases of the geometric mean IgG and IgM anti-LPS levels in the adults and teenagers: both conjugates elicited a greater than fourfold rise in the IgG anti-LPS level in serum in >/=80% of the volunteers. SPA-TT(2) elicited slightly higher, though not statistically significantly, levels of IgG anti-LPS than did SPA-TT(1) in these age groups. Accordingly, only SPA-TT(2) was evaluated in the 2- to 4-year-old children. On a random basis, one or two injections were administered 6 weeks apart to the children. No significant side effects were observed, and the levels of preexisting anti-LPS in serum were similar in children of all ages. A significant rise in the IgG anti-LPS titer was elicited by the first injection (P = 0.0001); a second injection did not elicit a booster response. Representative sera from all groups had bactericidal activity that could be adsorbed by S. enterica serovar Paratyphi A LPS.
Assuntos
Antígenos O/imunologia , Salmonella paratyphi A/imunologia , Toxoide Tetânico/imunologia , Adolescente , Adulto , Anticorpos Antibacterianos/sangue , Pré-Escolar , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Lipopolissacarídeos/imunologia , Vacinas Conjugadas/imunologiaRESUMO
A population-based surveillance for typhoid fever was conducted in three rural communes of Dong Thap Province in southern Vietnam (population 28,329) for a 12-month-period starting on December 4, 1995. Cases of typhoid fever were detected by obtaining blood for culture from residents with fever > or = 3 days. Among 658 blood cultures, 56 (8.5%) were positive for Salmonella typhi with an overall incidence of 198 per 10(5) population per year. The peak occurrence was at the end of the dry season in March and April. The attack rate was highest among 5-9 year-olds (531/10(5)/year), and lowest in > 30 year-olds (39/10(5)/year). The attack rate was 358/10(5)/year in 2-4 year-olds. The isolation of S. typhi from blood cultures was highest (17.4%) in patients with 5 to 6 days of fever. Typhoid fever is highly endemic in Vietnam and is a significant disease in both preschool and school-aged children.
Assuntos
Vigilância da População , População Rural , Salmonella typhi/isolamento & purificação , Febre Tifoide/epidemiologia , Adolescente , Adulto , Sangue/microbiologia , Criança , Pré-Escolar , Meios de Cultura , Humanos , Pessoa de Meia-Idade , Estações do Ano , Febre Tifoide/microbiologia , Febre Tifoide/fisiopatologia , Vietnã/epidemiologiaRESUMO
The capsular polysaccharide of Salmonella typhi, Vi, is an essential virulence factor and a protective vaccine for people older than 5 years. The safety and immunogenicity of two investigational Vi conjugate vaccines were evaluated in adults, 5- to 14-year-old children, and 2- to 4-year-old children in Vietnam. The conjugates were prepared with Pseudomonas aeruginosa recombinant exoprotein A (rEPA) as the carrier, using either N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP; Vi-rEPA(1)) or adipic acid dihydrazide (ADH; Vi-rEPA(2)) as linkers. None of the recipients experienced a temperature of >38.5 degrees C or significant local reactions. One injection of Vi-rEPA(2) into adults elicited a geometric mean (GM) increase in anti-Vi immunoglobulin G (IgG) from 9.62 enzyme-linked immunosorbent assay units/ml (EU) to 465 EU at 6 weeks; this level fell to 119 EU after 26 weeks. In the 5- to 14-year-old children, anti-Vi IgG levels at 6 weeks elicited by Vi-rEPA(2), Vi-rEPA(1), and Vi were 169, 22.8, and 18.9 EU, respectively (P = 0.0001 for Vi-rEPA(1) and Vi with respect to Vi-rEPA(2)). At 26 weeks, the anti-Vi IgG levels for recipients of Vi-rEPA(2), Vi-rEPA(1), and Vi were 30.0, 10.8, and 13.4 EU, respectively (P < 0.001 for Vi-rEPA(1) and Vi with respect to Vi-rEPA(2)); all were higher than the preinjection levels (P = 0. 0001). Vi-rEPA(2) also elicited the highest anti-Vi IgM and IgA levels of the three vaccines. In the 2- to 4-year-old children at 6 weeks following the first injection, Vi-rEPA(2) elicited an anti-Vi IgG level of 69.9 EU compared to 28.9 EU for Vi-rEPA(1) (P = 0.0001). Reinjection increased Vi antibody levels from 69.9 to 95.4 EU for Vi-rEPA(2) and from 28.9 to 83.0 EU for Vi-rEPA(1). At 26 weeks, anti-Vi IgG levels remained higher than those at preinjection (30.6 versus 0.18 for Vi-rEPA(2) and 12.8 versus 0.33 for Vi-rEPA(1); P = 0.0001 for both). Vi vaccine is recommended for individuals of 5 years of age or older. In the present study, the GM level of anti-Vi IgG elicited by two injections of Vi-rEPA(2) in the 2- to 4-year-old children was higher than that elicited by Vi in the 5- to 14-year-old children (30.6 versus 13.4; P = 0.0001). The safety and immunogenicity of the Vi-rEPA(2) conjugate warrant further investigation.
Assuntos
ADP Ribose Transferases , Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/imunologia , Toxinas Bacterianas , Vacinas Bacterianas/imunologia , Polissacarídeos Bacterianos/imunologia , Salmonella typhi/imunologia , Fatores de Virulência , Adolescente , Adulto , Fatores Etários , Antígenos de Bactérias/efeitos adversos , Vacinas Bacterianas/efeitos adversos , Pré-Escolar , Exotoxinas/imunologia , Humanos , Imunoglobulina A/sangue , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Polissacarídeos Bacterianos/efeitos adversos , Vacinas Conjugadas/imunologia , Exotoxina A de Pseudomonas aeruginosaRESUMO
Seroepidemiological data and a clinical trial with a Shigella sonnei O-specific polysaccharide (O-SP)-Pseudomonas aeruginosa recombinant exoprotein A (rEPA) conjugate provide evidence that a critical level of immunoglobulin G (IgG) lipopolysaccharide (LPS) antibodies in serum confers protection against shigellosis. We evaluated the immunogenicity of conjugates whose carrier proteins and O-SPs were treated with succinic anhydride (SA), which reacts with amino groups at neutral pH to form amide-linked carboxyls (succinylation). Conjugates were synthesized with either of two genetically inactivated medically useful toxins, the diphtheria protein CRM9 or rEPA, bound to the O-SP of Shigella flexneri type 2a. Conjugates composed of the succinylated protein, succinylated O-SP, or both succinylated components were administered to mice by a clinically relevant scheme, and their levels of serum IgG anti-LPS and anti-proteins were assayed 7 days after the second and third injections. CRM9 served as a more immunogenic carrier than rEPA. Conjugates composed of succinylated components were more immunogenic than the conjugates composed of the native components. SA treatment of both the carrier protein and the O-SP did not confer an advantage over the succinylated protein alone. Conjugates prepared with native proteins, in general, elicited slightly higher levels of IgG protein antibodies than conjugates composed of the SA-treated proteins.
Assuntos
Vacinas Bacterianas/imunologia , Antígenos O/imunologia , Shigella flexneri/imunologia , Anidridos Succínicos/farmacologia , Animais , Anticorpos Antibacterianos/sangue , Feminino , Camundongos , Vacinas Conjugadas/imunologiaRESUMO
O-specific polysaccharide conjugates of shigellae were safe and immunogenic in young adults, and a Shigella sonnei conjugate conferred protection [1-3]. Shigellosis is primarily a disease of children; therefore, the safety and immunogenicity of S. sonnei and Shigella flexneri 2a conjugates were studied in 4- to 7-year-old children. Local and systemic reactions were minimal. The first injection of both conjugates elicited significant rises in geometric mean levels of serum IgG only to the homologous lipopolysaccharide (LPS) (S. sonnei, 0.32-8.25 ELISA units [EU]; S. flexneri 2a, 1.15-20.5 EU; P<.0001). Revaccination at 6 weeks induced a booster response to S. flexneri 2a LPS (20.5-30.5 EU, P=.003). Six months later, the geometric mean levels of IgG anti-LPS for both groups were higher than the prevaccination levels (P<.0001). Similar, but lesser, rises were observed for IgM and IgA anti-LPS. The investigational Shigella conjugates were safe and immunogenic in children and merit evaluation of their efficacy.
Assuntos
Vacinas Bacterianas/uso terapêutico , Disenteria Bacilar/prevenção & controle , Imunoconjugados/uso terapêutico , Antígenos O/uso terapêutico , Shigella/imunologia , Vacinação , Anticorpos Antibacterianos/sangue , Especificidade de Anticorpos , Vacinas Bacterianas/efeitos adversos , Vacinas Bacterianas/imunologia , Criança , Pré-Escolar , Humanos , Imunoconjugados/efeitos adversos , Isotipos de Imunoglobulinas/sangue , Isotipos de Imunoglobulinas/imunologia , Antígenos O/efeitos adversos , Antígenos O/imunologia , Shigella flexneri/imunologia , Shigella sonnei/imunologiaRESUMO
Levels of IgG antibody to pertussis toxin (PT) and filamentous hemagglutinin (FHA) were measured in paired serum samples from 781 patients fulfilling at least one laboratory criterion for pertussis that was suggested by an ad hoc committee sponsored by the World Health Organization. The patients were participants or family members of participants in a double-blind efficacy trial of a monocomponent pertussis toxoid vaccine. Of 596 nonvaccinated children, 90% had significant (two-fold or more) rises in PT IgG and FHA IgG levels. Only 17 (32%) of 53 children previously vaccinated with three doses of pertussis toxoid had rises in PT IgG levels because they already had elevated PT IgG levels in their acute-phase serum samples. PT IgG and FHA IgG levels were significantly higher in acute-phase serum samples from 29 adults than in acute-phase serum samples from the nonvaccinated children. Nevertheless, significant rises in levels of PT IgG (79% of samples) and FHA IgG (90%) were demonstrated in adults. In conclusion, assay of PT IgG and FHA IgG in paired serum samples is highly sensitive for diagnosing pertussis in nonvaccinated individuals. Assay of PT IgG levels in paired sera is significantly less sensitive for diagnosis of pertussis for children vaccinated with pertussis toxoid.
Assuntos
Adesinas Bacterianas/imunologia , Anticorpos Antibacterianos/sangue , Hemaglutininas/imunologia , Imunoglobulina G/sangue , Toxina Pertussis , Vacina contra Coqueluche/imunologia , Fatores de Virulência de Bordetella/imunologia , Coqueluche/imunologia , Adulto , Antígenos de Bactérias/imunologia , Bordetella pertussis/imunologia , Toxoide Diftérico/administração & dosagem , Toxoide Diftérico/imunologia , Vacina contra Difteria e Tétano , Vacina contra Difteria, Tétano e Coqueluche/administração & dosagem , Vacina contra Difteria, Tétano e Coqueluche/imunologia , Método Duplo-Cego , Humanos , Lactente , Vacina contra Coqueluche/administração & dosagem , Toxoide Tetânico/administração & dosagem , Toxoide Tetânico/imunologia , Vacinação , Vacinas Combinadas/administração & dosagem , Vacinas Combinadas/imunologia , Coqueluche/prevenção & controleRESUMO
Standardization schemes devised by Control Agencies have followed clinical trials of experimental vaccines. The wealth of information about the pathogenesis of and immunity to bacteria, whose surface polysaccharides are protective antigens, now permits standardization to predict the efficacy of polysaccharide-based vaccines. There has been tacit acceptance of this notion with the licensure of groups Y and W135 meningococcal vaccines and of many of the pneumococcal types whose frequency in patients was too low for statistical significance to be assigned for their clinical efficacy. In fact, this was also the case for licensure of polio virus type 2 vaccine. We can reliably measure the level of anti-polysaccharide antibodies for meningococci, pneumococci, GBS and the Vi of S. typhi. Haemophilus type b conjugates have been reliably standardized by physico-chemical assays. New conjugates, therefore, may be licensed by data provided by standardization without awaiting the results of costly and time-consuming efficacy trials. Adoption of this scientifically-based approach to licensure will hasten the implementation of new and more effective vaccines.
Assuntos
Vacinas Conjugadas/normas , Vacinas Bacterianas/imunologia , Vacinas Bacterianas/normas , Criança , Vacinas contra Cólera/imunologia , Vacinas contra Cólera/normas , Controle de Medicamentos e Entorpecentes , Vacinas Anti-Haemophilus/imunologia , Vacinas Anti-Haemophilus/normas , Humanos , Neisseria meningitidis/imunologia , Vacinas Pneumocócicas , Polissacarídeos Bacterianos/imunologia , Padrões de Referência , Streptococcus agalactiae/imunologia , Streptococcus pneumoniae/imunologia , Vacinas Tíficas-Paratíficas/imunologia , Vacinas Tíficas-Paratíficas/normas , Vacinas Conjugadas/imunologiaAssuntos
Vacinas Bacterianas/normas , Imunoglobulina G/sangue , Adulto , Antitoxinas/sangue , Vacinas Bacterianas/imunologia , Vacinas Bacterianas/farmacologia , Ensaios Clínicos como Assunto/métodos , Feminino , Humanos , Lactente , Recém-Nascido , Polissacarídeos Bacterianos/imunologia , Gravidez , Padrões de Referência , Streptococcus agalactiae/imunologiaRESUMO
Conjugate vaccines were prepared by binding hydrazine-treated lipopolysaccharide (DeALPS) from Vibrio cholerae O1, serotype Inaba, to cholera toxin (CT) variants CT-1 and CT-2. Volunteers (n = 75) were injected with either 25 microg of DeALPS, alone or as a conjugate, or the licensed cellular vaccine containing 4 x 10(9) organisms each of serotypes Inaba and Ogawa per ml. No serious adverse reactions were observed. DeALPS alone did not elicit serum LPS or vibriocidal antibodies in mice and only low levels of immunoglobulin M (IgM) anti-LPS in the volunteers. Recipients of the cellular vaccine had the highest IgM anti-LPS levels, but the difference was not statistically significant from that elicited by the conjugates. The conjugates elicited the highest levels of IgG anti-LPS (DeALPS-CT-2 > DeALPS-CT-1 > cellular vaccine). Both conjugates and the cellular vaccine elicited vibriocidal antibodies: after 8 months, recipients of cellular vaccine had the highest geometric mean titer (1,249), followed by DeALPS-CT-2 (588) and DeALPS-CT-1 (330). The correlation coefficient between IgG anti-LPS and 2-mercaptoethanol (2-ME)-resistant vibriocidal antibodies was 0. 81 (P = 0.0004). Convalescent sera from cholera patients had a mean vibriocidal titer of 2,525 that was removed by treatment with 2-ME. The vibriocidal activities of sera from all vaccine groups and from the patients were absorbed (>75%) by LPS but not by either CT-1 or CT-2. Conjugate-induced IgG vibriocidal antibodies persisted longer than those elicited by the whole-cell vaccine. Both conjugates, but not the cellular vaccine, elicited IgG anti-CT.
Assuntos
Toxina da Cólera/imunologia , Vacinas contra Cólera/imunologia , Antígenos O/imunologia , Adolescente , Adulto , Animais , Anticorpos Antibacterianos/sangue , Células CHO , Cricetinae , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Mercaptoetanol/farmacologia , Camundongos , Vacinas Conjugadas/imunologia , Vibrio cholerae/imunologiaRESUMO
OBJECTIVE: In a previously reported double blind placebo-controlled trial it was shown that vaccination with pertussis toxoid during infancy reduced the incidence of pertussis in the vaccinees. Parents and siblings of participants in the trial were followed for pertussis to determine whether vaccination provided indirect protection of close contacts in a nonvaccinating country with a high incidence of pertussis. STUDY DESIGN: A group of 3450 infants were randomized to vaccination with diphtheria, tetanus and pertussis toxoids (DTPtxd) or to diphtheria and tetanus toxoids (DT). Pertussis cases were actively sought and diagnosed by cultures and serology in vaccinees (previously reported) and in family members during 2 years after the third vaccination. RESULTS: Pertussis as defined by the World Health Organization (paroxysmal cough of > or = 21 days and certain laboratory criteria) was diagnosed in 11 parents of DTPtxd recipients and in 26 parents of DT recipients; indirect protection was 60% (95% confidence intervals, 16 to 82%). In nonvaccinated younger siblings of DTPtxd and DT recipients there were 10 and 18 cases of pertussis, respectively; indirect protection was 43% (95% confidence intervals, -31 to 76%). When all cases of pertussis with cough > or = 7 days were included, the indirect protection was 44% (95% confidence intervals, 7 to 67%) in parents and 56% (95% confidence intervals, 9 to 81%) in younger siblings. CONCLUSION: Vaccination of children with pertussis toxoid reduces spread of pertussis to close contacts, which suggests that mass vaccination with pertussis toxoid would induce herd immunity.
Assuntos
Saúde da Família , Vacina contra Coqueluche , Vacinação , Coqueluche/prevenção & controle , Seguimentos , Humanos , Lactente , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
Escherichia coli O157 causes severe enteritis and the extraintestinal complication hemolytic-uremic syndrome. Serum IgG against the surface polysaccharide antigen, the O-specific polysaccharide of lipopolysaccharide (LPS), may confer protective immunity by lysing the inocula. In a phase 1 clinical study, three investigational vaccines were studied in 87 healthy adults. The vaccines were prepared by covalently binding E. coli O157 O-specific polysaccharide with Pseudomonas aeruginosa recombinant exoprotein A. No significant reactions were reported. Most volunteers (81%) responded with a > 4-fold increase in IgG LPS antibodies 1 week after vaccination; all volunteers responded with a > 4-fold rise at 4 weeks and this level was sustained for 26 weeks after injection. All three vaccines elicited high titers of serum bactericidal activity that roughly correlated with the serum IgG and IgM LPS antibody levels. A phase 2 study in young children is planned.
Assuntos
ADP Ribose Transferases , Toxinas Bacterianas , Infecções por Escherichia coli/prevenção & controle , Escherichia coli O157/imunologia , Exotoxinas/imunologia , Antígenos O/imunologia , Vacinas Conjugadas/imunologia , Fatores de Virulência , Adolescente , Adulto , Anticorpos Antibacterianos/análise , Anticorpos Antibacterianos/imunologia , Escherichia coli O157/genética , Exotoxinas/genética , Feminino , Humanos , Imunoglobulina G/análise , Imunoglobulina G/imunologia , Imunoglobulina M/análise , Imunoglobulina M/imunologia , Masculino , Pseudomonas aeruginosa/genética , Pseudomonas aeruginosa/imunologia , Proteínas Recombinantes de Fusão/imunologia , Vacinas Conjugadas/efeitos adversos , Exotoxina A de Pseudomonas aeruginosaRESUMO
As with diphtheria, immunity to pertussis is complex because it involves both individual and community protection against infection with B. pertussis. Although B. pertussis has at least five proteins required for virulence and an additional two "toxic" components, only serum neutralizing antibodies to PT (antitoxin) have been shown to confer immunity to pertussis.
Assuntos
Bordetella pertussis/imunologia , Vacina contra Coqueluche/imunologia , Coqueluche/imunologia , Criança , Pré-Escolar , Humanos , Vacina contra Coqueluche/uso terapêutico , Coqueluche/fisiopatologia , Coqueluche/prevenção & controleRESUMO
The Vi capsular polysaccharide of Salmonella typhi, a licensed vaccine for typhoid fever in individuals > or = 5 years old, induces low and short-lived antibodies in children, and reinjection does not elicit booster responses at any age. Its immunogenicity was improved by binding Vi to proteins by using N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) as a linker. Similar findings were observed with the structurally related, di-O-acetyl derivative of pectin [poly-alpha(1-->4)-D-GalpA] designated OAcP. Protein conjugates of Vi and OAcP were synthesized by carbodiimide-mediated synthesis with adipic acid dihydrazide (ADH) as the linker. Hydrazide groups were introduced into proteins (bovine serum albumin or recombinant Pseudomonas aeruginosa exoprotein A) by treatment with ADH and 1-ethyl-3(3-dimethylaminopropyl carbodiimide (EDC). The resultant adipic acid hydrazide derivatives (AH-proteins), containing 2.3 to 3.4% AH, had antigenic and physicochemical properties similar to those of the native proteins. The AH-proteins were bound to Vi and OAcP by treatment with EDC. The immunogenicity of Vi or OAcP, alone or as protein conjugates, was evaluated in young outbred mice and guinea pigs by subcutaneous injection of 2.5 and 5.0 microg, respectively, of polysaccharide, and antibodies were measured by enzyme-linked immunosorbent assay. All conjugates were significantly more immunogenic than Vi or OAcP alone and induced booster responses with 5- to 25-fold increases of antibodies. Vi conjugates were significantly more immunogenic than their OAcP analogs. A carboxymethyl derivative of yeast beta-glucan enhanced the anti-Vi response elicited by an OAcP conjugate but had no effect on the immunogenicity of Vi or of OAcP alone. Vi and OAcP conjugates synthesized by this scheme will be evaluated clinically.
Assuntos
Antígenos de Bactérias/imunologia , Vacinas Bacterianas/imunologia , Pectinas/imunologia , Polissacarídeos Bacterianos/imunologia , Salmonella typhi/imunologia , Adipatos , Adjuvantes Imunológicos/farmacologia , Animais , Feminino , Cobaias , Camundongos , Vacinas Conjugadas/imunologiaRESUMO
In a double-blind, placebo-controlled efficacy trial of a monocomponent pertussis toxoid vaccine, 3450 infants were randomly assigned to vaccination with diphtheria-tetanus toxoids with or without pertussis toxoid at 3, 5, and 12 months of age. Study children and family members were investigated for possible pertussis with cultures, serology, and polymerase chain reaction. Efficacy was 71% after 3 dose when the World Health Organization case definition of pertussis (which includes paroxysmal cough for 21 days or longer) was used. We report the efficacy in the subgroup of children who were exposed to pertussis in the household. Among study children exposed to pertussis in the household from the day of the third vaccination, 20 of 99 (20%) recipients of diphtheria-tetanus-pertussis toxoids vaccine and 64 of 79 (81%) recipients of diphtheria-tetanus toxoids vaccine had pertussis fulfilling criteria of the World Health Organization. The vaccine efficacy was 75% (95% confidence intervals 64% to 84%). In children who had received only two doses at the time of household exposure, vaccine efficacy was 66% (95% confidence intervals 15% to 90%) based on 4 cases among 32 household-exposed recipients of diphtheria-tetanus-pertussis toxoids vaccine and 13 cases among 35 household-exposed recipients of diphtheria-tetanus toxoids vaccine. In conclusion, the pertussis toxoid vaccine provides protection against pertussis both after household and community exposure.
Assuntos
Vacina contra Coqueluche/administração & dosagem , Toxoides/administração & dosagem , Coqueluche/prevenção & controle , Toxoide Diftérico/administração & dosagem , Vacina contra Difteria e Tétano , Vacina contra Difteria, Tétano e Coqueluche/administração & dosagem , Método Duplo-Cego , Saúde da Família , Humanos , Lactente , Toxoide Tetânico/administração & dosagem , Vacinas Combinadas/administração & dosagem , Coqueluche/diagnósticoRESUMO
BACKGROUND: In a previously reported double blind efficacy trial of a pertussis toxoid vaccine, 3450 infants were randomized to receive diphtheria-tetanus toxoids with or without pertussis toxoid at 3, 5 and 12 months of age. Efficacy against pertussis as defined by the World Health Organization was 71% from 30 days after the third vaccination with an average follow-up of 17.5 months. We now report efficacy for an additional 6 months of open follow-up. METHODS: Parents were contacted monthly by a nurse. If a participant or a family member coughed for > or = 7 days, a nasopharyngeal sample and paired sera were obtained. RESULTS: Efficacy during this open follow-up period was 77% (95% confidence intervals, 66 to 85%) based on 29 and 110 cases fulfilling the WHO definition of pertussis in vaccinated and control children, respectively. Efficacy against household exposure was 76% (95% confidence intervals, 51 to 91%). Pertussis in vaccinated children had a significantly shorter duration than pertussis in control children. Determination of pertussis toxin antibodies in paired sera with enzyme-linked immunosorbent assay had a lower diagnostic sensitivity in vaccinated (45%) than in control (92%) children, while determination of antibodies against filamentous hemagglutinin (not included in the vaccine) was highly sensitive for diagnosing pertussis in both groups (100 and 90%, respectively). CONCLUSIONS: A monocomponent pertussis toxoid vaccine induces significant protection against pertussis for at least 2 years after the third injection. To obtain an unbiased estimate of vaccine efficacy it is important to determine antibodies against an antigen that is not included in the vaccine.
Assuntos
Anticorpos Antibacterianos/biossíntese , Bordetella pertussis/imunologia , Vacina contra Difteria, Tétano e Coqueluche/imunologia , Toxoides/imunologia , Bordetella pertussis/isolamento & purificação , Pré-Escolar , Estudos de Coortes , Toxoide Diftérico/administração & dosagem , Toxoide Diftérico/imunologia , Vacina contra Difteria e Tétano , Vacina contra Difteria, Tétano e Coqueluche/administração & dosagem , Seguimentos , Humanos , Esquemas de Imunização , Lactente , Nasofaringe/microbiologia , Reação em Cadeia da Polimerase , Ensaios Clínicos Controlados Aleatórios como Assunto , Toxoide Tetânico/administração & dosagem , Toxoide Tetânico/imunologia , Vacinação , Vacinas Combinadas/administração & dosagem , Vacinas Combinadas/imunologiaRESUMO
Safflower (Carthamus tinctorius L. cv. S555) and spring wheat (Triticum aestivum L. cv. Anza) were grown with or without the arbuscular mycorrhizal fungus Glomus etunicatum Becker & Gerd., under environmentally controlled conditions. Soil phosphate concentrations were adjusted before planting to produce mycorrhizal (M) and non-mycorrhizal (NM) plants that had similar leaf areas and root length densities at the same stage of development before initiating drought stress treatments. Drought did not affect the amount of mycorrhizal infection in safflower or wheat. Interactions between water stress treatments and mycorrhizal infection on plant growth and phosphorus uptake were limited and only occurred in wheat. NM wheat plants had 28% greater shoot d. wt, slightly greater root length densities, and 39% greater P acquisition than M plants when grown under well watered conditions, but under droughted conditions plant size and tissue P contents of M and NM wheat plants were similar. Mycorrhizas did not affect stomatal behaviour during drought stress in either safflower or wheat, i.e., transpiration and stomatal conductance declined independently of infection as soil water was depleted and leaf water potentials declined. Therefore, mycorrhizal infection did not alter the intrinsic hydraulic properties of the plant/soil system. Whilst wheat maintained turgor of recently expanded leaves during severe drought and safflower did not, mycorrhizal infection had no effect on leaf turgor during drought in either plant species.